The precision cancer medicine Enhertu effectively targets HER2 over expressing NSCLC - trials ongoing.

KRAS a major driver of lung and other cancers for KRAS G12C mutated NSCLC - what patients need to know.

Keytruda is the standard of care for PD-1 + NSCLC. Longer follow continues to confirm advantage over chemotherapy.

Tecentriq® Checkpoint Inhibitor immunotherapy improves survival in early and advanced stage non-small cell lung cancers.

FDA Approves Rozlytrek for Treatment of ROS 1 NSCLC

Additional Evidence of Abraxane™ Activity in Advanced Non-small Cell Lung Cancer

The PD-1 checkpoint inhibitor Libtayo® improves survival compared with chemotherapy in NSCLC with > 50% PD-1 expression

Understand the role of precision cancer medicine, surgery, chemotherapy and radiation in the management of NSCLC.

Datopotamab is a novel precision medicine known as an antibody drug conjugate that targets HER2 + NSCLC

Amivantamab targets Non-Small Cell Lung Cancer with cancer causing EGFR Exon 20 Insertion Mutations

Tepmetkois a novel precision cancer medicine capable of targeting NSCLC with MET 14 exon skipping alterations

FDA grants breakthrough therapy status to Mobocertinib for treatment of patients with NSCLC and exon 20 mutations.

Immunotherapy with Tiragolumab + Tecentriq improves survival in NSCLC - gets FDA Breakthrough Therapy Designation.

ADAURA clinical trial confirms Tagrisso delays cancer progression of EGFRm NSCLC - Receives full FDA Approval.

Lobrena - a third generation ALK inhibitor drug with excellent CNS activity

Imfinzi immunotherapy significantly improves treatment of stage III NSCLC - 50% of patients survive 4 years .